Michael Lederman

Mobilizing Host Defenses to Lymphoid Sites of HIV Persistence to Induce Remission

National Institute of Allergy and Infectious Diseases · R56

PI · $897.7K · Emory University

Rustbelt Center for AIDS Research (Case/UHC-Pitt CFAR)

National Institute of Allergy and Infectious Diseases · P30

Contact PI · $13.4M · Case Western Reserve University

Regulatory T Cell Dysfunction in HIV-1/HCV Drug Users

National Institute on Drug Abuse · R01

Contact PI · $597.9K · Case Western Reserve University

Case Clinical Trials Unit

National Institute of Allergy and Infectious Diseases · UM1

Contact PI · $15.6M · Case Western Reserve University

Maraviroc (CCR5) Antagonism to Decrease the Incidence of the Immune Reconstitution Inflammatory Syndrome in HIV-Infected Patients

Principal investigator · Unknown

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

Maraviroc as an Immunomodulatory Drug for Antiretroviral-treated HIV Infected Patients Exhibiting Immunologic Failure

Principal investigator · Completed · Phase 4

University of California, San Francisco

Safety of and Immune Response to a Hepatitis B Virus Vaccine Given With a Booster (CpG7909 ODN) in HIV Infected and HIV Uninfected People

Principal investigator · Completed · Phase 1, Phase 2

National Institute of Allergy and Infectious Diseases (NIAID)

HIV Reservoir Reduction With Interleukin-2

Study chair · Terminated · Phase 2

Case Western Reserve University